Federal Register Notice: FDA has determined the regulatory review period for Eli Lilly’s Natroba (spinosad) is 2,261 days for extending patents which claim the human drug product. Natroba is indicated for the topical treatment of head lice infestations in patients four years of age and older. To view this notice, click here.
